Ces Urol 2001, 5(2):4-8 | DOI: 10.48095/cccu2001010

Uroselectivity of alfuzosin in treatment of patients with BPH symptoms

P. Navrátil

Urologická klinika FN a LF UK Hradec Králové

The number of 805 patients with BPH symptoms treated with alfuzosin for three months were included in the open multicentric study. Patients were treated with Xatral? 5SR 5mg twice a day without doses titration. Patients were monitored regularly every month during the studied period. We evaluated the International Prostatic Symptoms Score (l-PSS), questionnaire for benign prostatic hyperplasia of American Urology Association (AUA) and the erectile function, the blood pressure was monitored, we followed new medications and searched for adverse events. Main criteria of evaluation included safety and effectiveness of studied drug and drug influence on the life quality in the means of urinary symptoms and sexual functions. This study demonstrated options of medicamentous treatment of benign prostatic hyperplasia (BHP). The improvement of lower urinary tract symptoms with minimal occurrence of adverse events documented the clinical uroselectivity of alfuzosin together with its influence on the erectile functions of treated men. treated men.

Keywords: Alfuzosin, Clinical uroselectivity, Quality of life, Sexual functions, Benign prostatic hyperplasia

Published: March 1, 2001